[ Price : $8.95]
FDA accepts for review a Saol Therapeutics NDA resubmission for SL1009 (sodium dichloroacetate, or DCA), an investigational treatm...[ Price : $8.95]
FDA releases the 17-page form FDA-483 following a May inspection at Indias Strides Pharma Science drug manufacturing facility in B...[ Price : $8.95]
In its report on FY 2024 approvals of medical devices for pediatric uses, FDA says that 19 of the 56 device approvals that year we...[ Price : $8.95]
FDA releases the form FDA-483 with three observations from an inspection at the Novel Laboratories (Lupin) drug manufacturing faci...[ Price : $8.95]
NOTUS reports that FDA will reorganize on 10/1 to a shared services model in which administrative functions are centralized, and i...[ Price : $8.95]
A BioProcess International column says drug companies should design a controlled evidence ecosystem that can demonstrate to FDA in...[ Price : $8.95]
FDA encourages cancer clinical trial sponsors to adopt more flexible eligibility criteria related to washout periods and concomita...[ Price : $8.95]
A final FDA guidance urges sponsors of cancer clinical trials to broaden laboratory value-based eligibility criteria to reduce unn...